ESMO 2023: Updates in Non-Small Cell Lung Cancer (NSCLC)

home / post-conference-perspectives / esmo-2023-updates-in-non-small-cell-lung-cancer-nsclc

Patrick Forde, MBBCh, offers crucial perspectives on breakthroughs in Non-Small Cell Lung Cancer from ESMO 2023.

Episodes

Video 1 - "CheckMate 77T: Perioperative Immunotherapy in Resectable NSCLC"

November 10th 2023EP. 1: CheckMate 77T: Perioperative Immunotherapy in Resectable NSCLC

Patrick Forde, MBBCh, shares insights on perioperative immunotherapy in the CheckMate-77T study presented at ESMO 2023.

November 10th 2023EP. 2: Evolving NSCLC Landscape: Comparing Recent Updates in Neoadjuvant and Perioperative Immunotherapy

An expert comparison of recent data on neoadjuvant and perioperative immunotherapy in resectable early-stage NSCLC, including CheckMate 77T, CheckMate-816, and KEYNOTE-671.

Video 3 - "Updates in ALK+ NSCLC: ALINA Trial at ESMO 2023"

November 10th 2023EP. 3: Updates in ALK+ NSCLC: ALINA Trial at ESMO 2023

Patrick Forde, MBBCh, discusses ALK rearrangement in NSCLC and highlights ALINA trial results from ESMO 2023.

Video 4 - "Lessons From LIBRETTO-431 Trial in RET+ NSCLC"

November 17th 2023EP. 4: Lessons from LIBRETTO-431 Trial in RET+ NSCLC

An overview of data presented at ESMO 2023 on the LIBRETTO-431 trial of selpercatinib in RET+ NSCLC.

Video 5 - "PAPILLON Trial Insights: ESMO 2023"

November 17th 2023EP. 5: PAPILLON Trial Insights: ESMO 2023

Patrick Forde, MBBCh, discusses advances in EGFR Exon 20 insertion-mutated NSCLC.

Video 6 - "Innovations Needed and Future Directions in Treatment of NSCLC"

November 17th 2023EP. 6: Innovations Needed and Future Directions in Treatment of NSCLC

Concluding thoughts on data presented at ESMO 2023, and innovations still needed for improved survival of NSCLC—provided by Patrick Forde, MBBCh.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions